Literature DB >> 16751611

Molecular architecture of E. coli purine nucleoside phosphorylase studied by analytical ultracentrifugation and CD spectroscopy.

Anna Modrak-Wójcik1, Katarzyna Stepniak, Vladimir Akoev, Michał Zółkiewski, Agnieszka Bzowska.   

Abstract

Purine nucleoside phosphorylase (PNP) is a key enzyme of the nucleoside salvage pathway and is characterized by complex kinetics. It was suggested that this is due to coexistence of various oligomeric forms that differ in specific activity. In this work, the molecular architecture of Escherichia coli PNP in solution was studied by analytical ultracentrifugation and CD spectroscopy. Sedimentation equilibrium analysis revealed a homohexameric molecule with molecular mass 150+/-10 kDa, regardless of the conditions investigated-protein concentration, 0.18-1.7 mg/mL; presence of up to 10 mM phosphate and up to 100 mM KCl; temperature, 4-20 degrees C. The parameters obtained from the self-associating model also describe the hexameric form. Sedimentation velocity experiments conducted for broad protein concentration range (1 microg/mL-1.3 mg/mL) with boundary (classical) and band (active enzyme) approaches gave s(0)20,w=7.7+/-0.3 and 8.3+/-0.4 S, respectively. The molecular mass of the sedimenting particle (146+/-30 kDa), calculated using the Svedberg equation, corresponds to the mass of the hexamer. Relative values of the CD signal at 220 nm and the catalytic activity of PNP as a function of GdnHCl concentration were found to be correlated. The transition from the native state to the random coil is a single-step process. The sedimentation coefficient determined at 1 M GdnHCl (at which the enzyme is still fully active) is 7.7 S, showing that also under these conditions the hexamer is the only catalytically active form. Hence, in solution similar to the crystal, E. coli PNP is a hexameric molecule and previous suggestions for coexistence of two oligomeric forms are incorrect.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16751611      PMCID: PMC2242567          DOI: 10.1110/ps.062183206

Source DB:  PubMed          Journal:  Protein Sci        ISSN: 0961-8368            Impact factor:   6.725


  24 in total

1.  In vivo gene therapy of cancer with E. coli purine nucleoside phosphorylase.

Authors:  W B Parker; S A King; P W Allan; L L Bennett; J A Secrist; J A Montgomery; K S Gilbert; W R Waud; A H Wells; G Y Gillespie; E J Sorscher
Journal:  Hum Gene Ther       Date:  1997-09-20       Impact factor: 5.695

2.  Oligomeric structure of mammalian purine nucleoside phosphorylase in solution determined by analytical ultracentrifugation.

Authors:  Joachim Behlke; Gertraud Koellner; Agnieszka Bzowska
Journal:  Z Naturforsch C J Biosci       Date:  2005 Nov-Dec

3.  Purine nucleoside phosphorylase. Allosteric regulation of a dissociating enzyme.

Authors:  P A Ropp; T W Traut
Journal:  J Biol Chem       Date:  1991-04-25       Impact factor: 5.157

4.  Active enzyme centrifugation.

Authors:  D L Kemper; J Everse
Journal:  Methods Enzymol       Date:  1973       Impact factor: 1.600

5.  Calf spleen purine nucleoside phosphorylase: complex kinetic mechanism, hydrolysis of 7-methylguanosine, and oligomeric state in solution.

Authors:  Agnieszka Bzowska
Journal:  Biochim Biophys Acta       Date:  2002-04-29

Review 6.  Purine nucleoside phosphorylases: properties, functions, and clinical aspects.

Authors:  A Bzowska; E Kulikowska; D Shugar
Journal:  Pharmacol Ther       Date:  2000-12       Impact factor: 12.310

7.  A continuous spectrophotometric assay for inorganic phosphate and for measuring phosphate release kinetics in biological systems.

Authors:  M R Webb
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-01       Impact factor: 11.205

8.  Crystal structure of the ternary complex of E. coli purine nucleoside phosphorylase with formycin B, a structural analogue of the substrate inosine, and phosphate (Sulphate) at 2.1 A resolution.

Authors:  G Koellner; M Luić; D Shugar; W Saenger; A Bzowska
Journal:  J Mol Biol       Date:  1998-07-03       Impact factor: 5.469

9.  Structure-based design of inhibitors of purine nucleoside phosphorylase. 1. 9-(arylmethyl) derivatives of 9-deazaguanine.

Authors:  J A Montgomery; S Niwas; J D Rose; J A Secrist; Y S Babu; C E Bugg; M D Erion; W C Guida; S E Ealick
Journal:  J Med Chem       Date:  1993-01-08       Impact factor: 7.446

10.  Suicide gene/prodrug therapy for pancreatic adenocarcinoma by E. coli purine nucleoside phosphorylase and 6-methylpurine 2'-deoxyriboside.

Authors:  Sophie Deharvengt; Séverine Wack; Muriel Uhring; Marc Aprahamian; Amor Hajri
Journal:  Pancreas       Date:  2004-03       Impact factor: 3.327

View more
  4 in total

1.  Analysis of Soluble protein complexes in Shigella flexneri reveals the influence of temperature on the amount of lipopolysaccharide.

Authors:  Chang Niu; Na Shang; Xiang Liao; Erling Feng; Xiankai Liu; Dongshu Wang; Jie Wang; Peitang Huang; Yuejin Hua; Li Zhu; Hengliang Wang
Journal:  Mol Cell Proteomics       Date:  2013-02-02       Impact factor: 5.911

2.  Role of ionization of the phosphate cosubstrate on phosphorolysis by purine nucleoside phosphorylase (PNP) of bacterial (E. coli) and mammalian (human) origin.

Authors:  Anna Modrak-Wójcik; Aneta Kirilenko; David Shugar; Borys Kierdaszuk
Journal:  Eur Biophys J       Date:  2007-07-17       Impact factor: 1.733

3.  Applications of analytical ultracentrifugation to protein size-and-shape distribution and structure-and-function analyses.

Authors:  Chi-Yuan Chou; Yi-Hui Hsieh; Gu-Gang Chang
Journal:  Methods       Date:  2010-11-16       Impact factor: 3.608

4.  Purine nucleoside phosphorylase targeted by annexin v to breast cancer vasculature for enzyme prodrug therapy.

Authors:  John J Krais; Olivier De Crescenzo; Roger G Harrison
Journal:  PLoS One       Date:  2013-10-03       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.